<SEC-DOCUMENT>0000950170-25-038879.txt : 20250313
<SEC-HEADER>0000950170-25-038879.hdr.sgml : 20250313
<ACCEPTANCE-DATETIME>20250313171407
ACCESSION NUMBER:		0000950170-25-038879
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250313
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250313
DATE AS OF CHANGE:		20250313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SUTRO BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001382101
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452441988
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38662
		FILM NUMBER:		25736814

	BUSINESS ADDRESS:	
		STREET 1:		111 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-392-8412

	MAIL ADDRESS:	
		STREET 1:		111 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUTRO BIOPHARMA INC
		DATE OF NAME CHANGE:	20061127
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>stro-20250313.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T15:10:25.6087+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:stro="http://www.sutrobio.com/20250313" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_de36181c-a74f-4b46-a571-b8146418811d" name="dei:EntityCentralIndexKey" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c">0001382101</ix:nonNumeric><ix:nonNumeric id="F_5c184e43-1ebc-430e-9bd7-17e76945928b" name="dei:AmendmentFlag" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="stro-20250313.xsd"/></ix:references><ix:resources><xbrli:context id="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001382101</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-13</xbrli:startDate><xbrli:endDate>2025-03-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f833bdec-8bd1-4289-974e-76fb7075e259" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:7pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_830aec2f-88e0-465b-8940-0385e6b61359" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 13, 2025</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4983a5c4-89c6-4481-b8b7-cb3a2c038dc9" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUTRO BIOPHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.327%;box-sizing:content-box;"/>
    <td style="width:33.327%;box-sizing:content-box;"/>
    <td style="width:33.347%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_40305bf9-1b23-4ff2-8d4c-7ef4e8584618" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_84046c10-d348-48df-95bb-c4c3632832cc" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-38662</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ed92b8d3-e483-463a-ab9e-df2f838a6426" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-0926186</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f09c9968-7357-432b-906f-e193002e8821" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111 Oyster Point Blvd,</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bb950a0-237d-403a-a24e-be8f0c56e6a2" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_760cd242-53ea-49c8-8d87-5ac2d499e651" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c8bd0f3-3053-4635-8a57-9fb9c2d28381" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices) (Zip Code)</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3d18a38-eedf-4d44-8360-b4d7edae8074" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad7f8557-466a-4144-9743-7e7a82941d69" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">881-6500</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former name or former address, if changed since last report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49fc3202-9986-429a-b0f4-feab39c4a045" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_453aea30-e46d-42be-ba5c-cd5a24f74059" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_580b5508-e6df-476e-8ca5-b550f1490db5" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f50c4fe-585a-411a-bfcd-4f08fd341a12" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_43138228-4a65-4091-9606-b1eb8671a86a" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2babd2e4-4332-4869-bb41-a4e171862c0c" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">STRO</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_28bb3a3c-75a7-42a5-85db-1a491bde0d8b" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:66.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b674f94-1cad-4d87-90c3-295a1bfa895d" contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, Sutro Biopharma, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.05 Costs Associated with Exit or Disposal Activities</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, the Company announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned preclinical programs in its next-generation ADC pipeline, beginning with its potentially best-in-class exatecan ADC targeting Tissue Factor, STRO 004, expected to enter the clinic in the second half of 2025. As a result of the reprioritization, the Company announced plans to deprioritize additional investment into the development of luveltamab tazevibulin, or STRO-002 or luvelta. As part of the corporate restructuring, the Company plans to deprioritize luvelta-related activities, principally across clinical and manufacturing functions. The Company will continue to explore global outlicensing opportunities for luvelta. In addition, given the Company&#8217;s significant progress in fully externalizing its cell-free manufacturing to scale, the Company intends to exit its internal GMP manufacturing facility by year-end. The Company also plans to reduce its workforce by approximately 50%.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total cash payments and costs related to deprioritizing luvelta-related activities and reducing the workforce are estimated to be approximately $40 million to $45 million, with a significant majority of these amounts expected to be paid in 2025.  Approximately $20 million to $25 million will be incurred in connection with deprioritizing luvelta-related activities and the remaining approximately $20 million will be incurred in connection with the workforce reduction. These estimates are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the corporate restructuring.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the press release announcing the corporate restructuring is attached as Exhibit 99.2 to this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer Separation and Transition Agreement</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, the Company and William J. Newell, the President, Chief Executive Officer (&#8220;CEO&#8221;) and Director of the Company, entered into a Separation Agreement (the &#8220;Newell Separation and Transition Agreement&#8221;) following the mutual agreement between the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and Mr. Newell regarding transition of leadership of the Company and his departure from his current positions with the Company. Pursuant to the Newell Separation and Transition Agreement, Mr. Newell ceased his role as the Company&#8217;s President and CEO, effective March 13, 2025, following the filing with the Securities and Exchange Commission of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 (the &#8220;Newell Separation Date&#8221;), and resigned as a director of the Board, effective as of the Newell Separation Date. In addition, pursuant to the Newell Separation and Transition Agreement, Mr. Newell will continue to provide services to the Company, including</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reasonable transition services or such other services as the Company may request, through and until May 1, 2025. This mutual agreement was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Mr. Newell&#8217;s execution of a general release and waiver of claims and the terms of the Newell Separation and Transition Agreement, Mr. Newell will be entitled to receive the following benefits: (i) two cash payments totaling the gross amount of $1,066,500.00, equal to 150% of his annual salary, with the first payment paid in 2025 and the second payment paid on January 15, 2026; (ii) eighteen months of accelerated vesting on all equity awards under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;Plan&#8221;), (iii) a lump sum payment reflecting Mr. Newell&#8217;s bonus opportunity for the 2025 fiscal year on a pro-rated basis, based on the Company&#8217;s percentage  achievement of the Company&#8217;s 2025 corporate goals, as determined by the Board, and to be paid at the same time the Company pays its year-end 2025 bonuses (the &#8220;2026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bonus Payment Date&#8221;); (iv) and coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;Cobra&#8221;) paid for by the Company for up to 18 months beginning June 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Newell Separation and Transition Agreement is qualified in its entirety by reference to the complete text of the Newell Separation and Transition Agreement, a copy of which will be filed with the Company&#8217;s Quarterly Report on Form 10-Q for the three months ending March 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Board Appointment</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective as of the Newell Separation Date, the Board appointed Jane Chung, the Company&#8217;s President and Chief Operating Officer, to succeed Mr. Newell as Chief Executive Officer. Ms. Chung, age 54, has served as the Company&#8217;s President and Chief Operating Officer since December 2023 and previously served as the Company&#8217;s Chief Commercial Officer from August 2021 to December 2023. The Board also appointed Ms. Chung as a Class II Director of the Company, effective as of the Newell Separation Date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with Ms. Chung&#8217;s appointment as Chief Executive Officer, the Company entered into an amended offer letter with Ms. Chung (the &#8220;Chung Offer Letter&#8221;). Pursuant to the Chung Offer Letter, Ms. Chung will (i) receive a base salary of $675,000 effective as of the Newell Separation Date, (ii) be eligible to earn a target bonus of 60% of her base salary and (iii) be granted an award of 620,000 stock options and an award of 310,000 restricted stock units, both awards to be granted at the time of the Company&#8217;s annual 2025 refresh equity grants. Ms. Chung will continue to be a participant in the Company&#8217;s Change of Control and Severance Plan (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CIC Severance Plan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) as a Tier 1 Participant as defined in the CIC Severance Plan</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From May 2015 to August 2021, Ms. Chung served in several leadership roles at AstraZeneca, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from May 2013 to May 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From October 2003 to May 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc. and on non-profit boards in the science, education, and community development arenas. Ms. Chung received a B.S. in Pharmacy from St. John's University and a B.A. in Psychology from Columbia University.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no arrangements or understandings between Ms. Chung and any other persons, pursuant to which she was appointed as Chief Executive Officer, there are no family relationships among any of the Company&#8217;s directors or executive officers and Ms. Chung, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Chung Offer Letter is qualified in its entirety by reference to the complete text of the Chung Offer Letter, a copy of which will be filed with the Company&#8217;s Quarterly Report on Form 10-Q for the three months ending March 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ms. Chung is also party to the Company&#8217;s standard form of indemnification agreement. The form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Form S-1/A filed by the Company with the Securities and Exchange Commission (SEC) on September 17, 2018, and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer Separation and Transition Agreement</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, the Company and Edward C. Albini, the Chief Financial Officer (&#8220;CFO&#8221;) of the Company, entered into a Separation and Transition Services Agreement (the &#8220;Albini Separation and Transition Services Agreement&#8221;) following the mutual agreement between the Board and Mr. Albini regarding his transition from his current position with the Company, effective as of May 15, 2025 (the &#8220;Albini Transition Date&#8221;). This mutual agreement was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Mr. Albini&#8217;s execution of a general release and waiver of claims and the terms of the Albini Separation and Transition Services Agreement, Mr. Albini will be entitled to receive the following benefits: (i) two cash payments totaling the gross amount of $629,375.40, equal to 125% of his annual salary, with the first payment paid in 2025 and the second payment paid on January 15, 2026; (ii) fifteen months of accelerated vesting on all equity awards under the Plan, (iii) a lump sum payment reflecting Mr. Albini&#8217;s bonus opportunity for the 2025 fiscal year on a pro-rated basis, based on the Company&#8217;s percentage achievement of the Company&#8217;s 2025 corporate goals, as determined by the Board, and to be paid on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the 2026 Bonus Payment Date and (iv) and coverage under Cobra paid for by the Company for up to 15 months beginning June 1, 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Albini Separation and Transition Services Agreement is qualified in its entirety by reference to the complete text of the Albini Separation and Transition Services Agreement, a copy of which will be filed with the Company&#8217;s Quarterly Report on Form 10-Q for the three months ending March 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Medical Officer Separation and Transition Services Agreement</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 13, 2025, the Company and Dr. Anne Borgman, the Chief Medical Officer (&#8220;CMO&#8221;) of the Company, entered into a Separation and Transition Services Agreement (the &#8220;Borgman Separation and Transition Services Agreement&#8221;) following the mutual agreement between the Board and Dr. Borgman regarding her transition from her current position with the Company, effective as of March 13, 2025 (the &#8220;Borgman Transition Date&#8221;). Pursuant to the Borgman Separation and Transition Services Agreement, Dr. Borgman will continue to provide services to the Company, including reasonable transition services and such other services as the Company may request, through and until May 1, 2025, and serve as a consultant to the Company. This mutual agreement was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Dr. Borgman&#8217;s execution of a general release and waiver of claims and the terms of the Borgman Separation and Transition Services Agreement, Dr. Borgman will be entitled to receive the following benefits: (i) two cash payments totaling the gross amount of $643,750.00, equal to 125% of her annual salary, with the first payment paid in 2025 and the second payment paid on January 15, 2026; (ii) fifteen months of accelerated vesting on all equity awards under the Plan, (iii) a lump sum payment reflecting Dr. Borgman&#8217;s bonus opportunity for the 2025 fiscal year on a pro-rated basis, based on the percentage achievement of the Company&#8217;s 2025 corporate goals, as determined by the Board, and to be paid on the 2026 Bonus Payment Date and (iv) and coverage under Cobra paid for by the Company for up to 15 months beginning June 1, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Borgman Separation and Transition Services Agreement is qualified in its entirety by reference to the complete text of the Borgman Separation and Transition Services Agreement, a copy of which will be filed with the Company&#8217;s Quarterly Report on Form 10-Q for the three months ending March 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01.	Financial Statements and Exhibits</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.16%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:82.82%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Number</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="stro-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Sutro Biopharma, Inc. regarding its financial results for the year ended December 31, 2024, dated March 13, 2025.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="stro-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release issued by Sutro Bipharma, Inc. announcing the completion of its strategic portfolio review resulting in the prioritization of its Next-Generation ADC Pipeline.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Current Report on Form 8-K contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the Company&#8217;s corporate restructuring, its strategic portfolio review and the prioritization of its three wholly-owned preclinical programs in its next-generation ADC pipeline, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company&#8217;s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 13, 2025. Any of these risks and uncertainties could materially and adversely affect the Company&#8217;s results of operations, which would, in turn, have a significant and adverse impact on the Company&#8217;s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURE</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.96%;box-sizing:content-box;"/>
    <td style="width:3.06%;box-sizing:content-box;"/>
    <td style="width:36.98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sutro Biopharma, Inc.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 13, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Edward Albini</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Edward Albini</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>stro-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.3in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img217863751_0.jpg" alt="img217863751_0.jpg" style="width:159px;height:37px;"></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013;Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition&#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">SOUTH SAN FRANCISCO, Calif., March 13, 2025 &#x2013; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2024 and recent business highlights. The Company also announced the completion of a strategic portfolio review resulting in the prioritization of its next-generation ADC pipeline. A conference call will be held today at 2:00 p.m. PT/ 5:00 p.m. ET to discuss the pipeline reprioritization, team restructuring and next steps.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Full Year 2024 Financial Highlights</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash, Cash Equivalents and Marketable Securities</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $316.9 million, as compared to $388.3 million as of September 30, 2024. Cash runway is expected into at least Q4 2026, excluding anticipated milestones from existing collaborations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Revenue</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Revenue was $62.0 million for the year ended December 31, 2024, as compared to $153.7 million for the year ended December 31, 2023, with the 2024 amount related principally to the Astellas collaboration and the Tasly agreement. Future collaboration and license revenue under existing agreements, and from any additional collaboration and license partners, will fluctuate as a result of the amount and timing of revenue recognition of upfront, milestones, and other agreement payments.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating Expenses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses for the year ended December 31, 2024 were $300.5 million, as compared to $243.0 million for year ended December 31, 2023. The year 2024 includes non-cash expenses for stock-based compensation of $24.7 million and depreciation and amortization of $7.2 million, as compared to $24.9 million and $6.8 million, respectively, in the year 2023. Total operating expenses for the year ended December 31, 2024 were comprised of research and development expenses of $252.0 million and general and administrative expenses of $48.5 million.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Restructuring Expenditures:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Cash payments resulting from the strategic portfolio review and related restructuring are estimated to be $40 to $45 million. Cost reductions subsequently realized from the restructuring, combined with refocused clinical development priorities give the Company an expected cash runway into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call Details:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company will host a conference call and webcast today at 2:00 p.m. PT/ 5:00 p.m. ET. The webcast information will also be available through the News &amp; Events section of the Investors portion of the Company&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.sutrobio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. An archived replay will be available for at least 30 days after the event.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img217863751_0.jpg" alt="img217863751_0.jpg" style="width:159px;height:37px;"></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Sutro Biopharma</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro&#x2019;s fit-for-purpose technology, including cell-free XpressCF&#174;, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media&#x202f;@Sutrobio, or visit www.sutrobio.com.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, including enrollment and site activation; timing of announcements of clinical results, trial initiation, and regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company&#x2019;s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company&#x2019;s product candidates; the timing of exiting the manufacturing facility in San Carlos; the timing and receipt of anticipated future milestone payments; the Company&#x2019;s expected cash runway; and  the expected costs and cost reductions associated with the restructuring. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company&#x2019;s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company&#x2019;s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates,, the market size for the Company&#x2019;s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company&#x2019;s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company&#x2019;s ability to fund development activities and achieve development goals, the Company&#x2019;s ability to protect intellectual property, and the Company&#x2019;s commercial collaborations with third parties and other risks and uncertainties described under the heading &#x201c;Risk Factors&#x201d; in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Emily White</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(650) 823-7681</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	 </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ewhite@sutrobio.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Amy Bonanno</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Lyra Strategic Advisory</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">abonanno@lyraadvisory.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.3in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img217863751_0.jpg" alt="img217863751_0.jpg" style="width:159px;height:37px;"></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Statements of Operations Financial Data</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share amounts)</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.54%;box-sizing:content-box;"></td>
    <td style="width:2.995%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:5.587%;box-sizing:content-box;"></td>
    <td style="width:5.587%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:1.109%;box-sizing:content-box;"></td>
    <td style="width:13.713%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:1.109%;box-sizing:content-box;"></td>
    <td style="width:12.687%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
    <td style="width:1.109%;box-sizing:content-box;"></td>
    <td style="width:16.853%;box-sizing:content-box;"></td>
    <td style="width:0.964%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="13" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the year ended December 31</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2022</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Revenues</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">62,043</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">153,731</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">67,772</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">252,043</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">180,425</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">137,171</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">48,453</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">62,584</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">59,544</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">300,496</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">243,009</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">196,715</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(238,453</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(89,278</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(128,943</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Interest income</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">18,643</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">14,510</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3,455</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Unrealized gain on equity securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">-</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9,917</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">12,130</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Non-cash interest expense related to the</font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;sale of future royalties</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(31,070</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(12,570</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">-</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Interest and other income (expense), net</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,782</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(11,180</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(3,346</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss before provision for income taxes</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(225,098</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(88,601</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(116,704</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Provision for income taxes</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,363</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">18,192</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2,500</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(227,461</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(106,793</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(119,204</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(2.96</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(1.78</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(2.35</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12.95pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average shares used in</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;computing basic and diluted net loss</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.556%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;per share</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">76,829,198</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">60,163,542</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">50,739,185</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected Balance Sheets Financial Data</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(In thousands)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:1pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.84%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.22%;box-sizing:content-box;"></td>
    <td style="width:15.36%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.22%;box-sizing:content-box;"></td>
    <td style="width:14.36%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2024</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(1)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2023</font><font style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:'Calibri',sans-serif;position:relative;font-kerning:none;min-width:fit-content;">(2)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and marketable securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">316,895</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">333,681</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investment in equity securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">-</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">41,937</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accounts receivable</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8,616</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">36,078</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">18,190</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">21,940</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">17,677</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">22,815</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Other assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">25,829</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">14,285</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">387,207</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">470,736</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accounts payable, accrued expenses and other liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">56,324</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">64,293</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Deferred revenue</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">82,319</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">74,045</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:2.533%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating lease liability</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">23,154</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">29,574</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Debt</font><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">-</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4,061</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Deferred royalty obligation related to the sale of future royalties</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">180,809</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">149,114</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">342,606</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">321,087</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">44,601</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">149,649</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ccecff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total Liabilities and Stockholders&#x2019; Equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">387,207</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">470,736</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(1)</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The condensed balance sheet as of  December 31, 2024 was derived from the unaudited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 13, 2025.</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.69pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(2)	</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The condensed balance sheet as of December 31, 2023 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 25, 2024.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>stro-ex99_2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html>
 <head>
  <title>EX-99.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img218787272_0.jpg" alt="img218787272_0.jpg" style="width:192px;height:62px;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">	</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:13pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations &#x2013;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">&#x2013; Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">SOUTH SAN FRANCISCO, Calif., March 13, 2025 &#x2013; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned preclinical programs in its next-generation ADC pipeline, beginning with its potentially best-in-class exatecan ADC targeting Tissue Factor, STRO 004, expected to enter the clinic in the second half of 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Additionally, the Company announced that it is deprioritizing additional investment into development of luvelta across all indications and is reducing headcount by nearly 50 percent. The Company will continue to explore global out-licensing opportunities for luvelta, as Sutro still believes in its potential to provide significant benefit to patients with unmet need. Further, given Sutro&#x2019;s significant progress in fully externalizing its cell-free manufacturing to scale, the Company intends to exit its internal GMP manufacturing facility by year-end. As a result of this strategic review and reprioritization, the Company&#x2019;s cash runway is expected into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company also announced that Bill Newell and Sutro&#x2019;s Board of Directors have mutually agreed that it is the right time to transition leadership. Jane Chung, President and Chief Operating Officer, will assume the responsibilities of Chief Executive Officer and Board member from Mr. Newell, effective today. Mr. Newell will continue to be available at the Company&#x2019;s request in an advisory capacity through the transition.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;It has been a privilege to be the CEO of Sutro, and I am proud of what the team has accomplished. As the Company begins this exciting new phase, I want to express my utmost confidence in Jane to advance the Company&#x2019;s leadership in next-generation ADCs,&#x201d; said Bill Newell. &#x201c;The decision to reallocate resources from the development of luvelta was difficult, as we remain steadfast in our belief in its significant potential to benefit patients with cancer. Most importantly, we would like to thank the patients, their families, clinicians, partners and employees who made our luvelta program possible.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">111 Oyster Point Blvd South San Francisco, CA 94080   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">T: </font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">650-881-6500   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">F:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> 650.553.9659  </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">W:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> sutrobio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img218787272_0.jpg" alt="img218787272_0.jpg" style="width:192px;height:62px;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">	</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Our strategic portfolio review determined that the best path forward is to prioritize our next-generation exatecan and dual-payload ADC programs,&#x201d; said Jane Chung, Sutro&#x2019;s Chief Executive Officer. &#x201c;This shift in focus will result in considerable reduction of operating costs and allow us to chart a new future for Sutro. We believe the programs we selected are high-value, potentially best-in-class candidates that harness our unique ability to address the most complex biology. Over the next three years, we plan to file three INDs for our wholly-owned programs. In addition, Sutro remains committed to our existing strategic collaborations which have the potential to generate up to $2 billion in milestone payments, in addition to royalties.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Commented Connie Matsui, Sutro&#x2019;s Board Chair: &#x201c;We are grateful for Bill&#x2019;s many years of service and dedication to Sutro, in particular for leading the development of our trailblazing cell-free platform, and for his support of the Company&#x2019;s new direction. We are also appreciative of the many significant contributions made by the employees who are departing.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Pipeline Priorities and Organizational Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Wholly-Owned Sutro Programs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">STRO-004:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Sutro&#x2019;s novel exatecan Tissue Factor ADC, has been prioritized as the Company&#x2019;s lead program, with an initial focus in solid tumors. The Company is preparing to submit an IND in the second half of 2025. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">STRO-006:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Sutro&#x2019;s differentiated integrin beta-6 ADC is expected to enter clinical development in 2026 aimed at multiple solid tumors. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Dual-Payload Program: A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">n IND for</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro&#x2019;s first wholly-owned dual-payload ADC is anticipated to be filed in 2027.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Existing Collaborations for Next-Generation ADCs</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Ipsen:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> A drug development program is ongoing with Ipsen for STRO-003, a ROR1 ADC.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Astellas:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Two research and development programs are ongoing with Astellas for dual-payload immunostimulatory ADCs (iADCs). <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">These collaborations remain a strategic priority given their long-term value creation potential and the increasing relevance of specialized ADCs in the treatment of cancer.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Organization</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Headcount and Operations: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As part of this restructuring, Sutro will reduce its organizational headcount by nearly 50 percent. These changes are in process and are expected to be substantially complete by the end of 2025. Manufacturing capabilities to support the next-generation ADC pipeline have been fully established and scaled up externally.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As a result, Sutro&#x2019;s operations at its manufacturing facility in San Carlos are expected to cease by year end 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Management: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Jane Chung, President and Chief Operating Officer, will assume the responsibilities as Chief Executive Officer and will be appointed as a member of the Board today. Bill Newell is stepping down as Chief Executive Officer and as a member of the Board, also effective today. He will continue to be available at the Company&#x2019;s request in an advisory capacity through the transition. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">111 Oyster Point Blvd South San Francisco, CA 94080   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">T: </font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">650-881-6500   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">F:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> 650.553.9659  </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">W:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> sutrobio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img218787272_0.jpg" alt="img218787272_0.jpg" style="width:192px;height:62px;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">	</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Financial</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Restructuring Expenditures:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Cash payments associated with this decision are estimated to be $40 to $45 million. Cost reductions subsequently realized from the restructuring, combined with refocused clinical development priorities give the Company an expected cash runway into at least the fourth quarter of 2026, excluding anticipated milestones from existing collaborations. The Company reports cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Luvelta Deprioritization:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Despite promising clinical data, the Company made the difficult decision to deprioritize additional investment into development of luvelta and focus its resources on its early pipeline. Sutro continues to explore out-licensing opportunities to deliver the promise of luvelta&#x2019;s benefit to patients with unmet need in platinum resistant ovarian cancer and beyond.   </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company will host a conference call and webcast today at 2:00 p.m. PT/ 5:00 p.m. ET. The webcast information will also be available through the News &amp; Events section of the Investors portion of the Company&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.sutrobio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. An archived replay will be available for at least 30 days after the event.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About Sutro Biopharma</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro&#x2019;s fit-for-purpose technology, including cell-free XpressCF&#174;, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media&#x202f;@Sutrobio, or visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.sutrobio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, including enrollment and site activation; timing of announcements of clinical results, trial initiation, and regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company&#x2019;s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company&#x2019;s product candidates; the timing of exiting the manufacturing facility in San Carlos; the timing and receipt of anticipated future milestone payments; the Company&#x2019;s expected cash runway; and  the expected costs and cost reductions associated with the restructuring. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company&#x2019;s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">111 Oyster Point Blvd South San Francisco, CA 94080   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">T: </font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">650-881-6500   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">F:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> 650.553.9659  </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">W:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> sutrobio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img218787272_0.jpg" alt="img218787272_0.jpg" style="width:192px;height:62px;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">	</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates,, the market size for the Company&#x2019;s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company&#x2019;s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company&#x2019;s ability to fund development activities and achieve development goals, the Company&#x2019;s ability to protect intellectual property, and the Company&#x2019;s commercial collaborations with third parties and other risks and uncertainties described under the heading &#x201c;Risk Factors&#x201d; in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Emily White</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Sutro Biopharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(650) 823-7681</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">	 </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">ewhite@sutrobio.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Amy Bonanno</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Lyra Strategic Advisory</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">abonanno@lyraadvisory.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"># # #</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">111 Oyster Point Blvd South San Francisco, CA 94080   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">T: </font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">650-881-6500   </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">F:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> 650.553.9659  </font><font style="color:#2f5496;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">W:</font><font style="color:#808080;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> sutrobio.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img217863751_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img217863751_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  E )\# 2(  A$! Q$!_\0
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M4MK>/3]:A>*6-QYK/(65E^4#/-?IG_PY'_:X_P"CX3_W_P#B9_\ -%7Y1_\
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MK%K/CA/ D?BW7;:"-;.VUK6;^"Q"V<<"K^&_[+?_  26_P""?W_!1W_@H_\
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)V^]TF_O>I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img218787272_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img218787272_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ , # 2(  A$! Q$!_\0
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MJU79>9ZKYP[AAVYH\X<?*U>9_$GXY:)\,_"^F:[J45Q):7^WRUB3<PRH89_
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M9'NH1+;QG^+>F/O9]<_2OJ^'Q[^S[JD:0*?"I&/ECDTU!C\XZTO$'[-_PO\
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M(FFVGC2P0G$T3""Z([ I]TGW KE]:^/GQ-D5X-+^$NI1SMP)+K.P>^5-<_\
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M_!,7P5)\/X=$T3Q9XEL[K3QYVE&XU R6UM<@[ED\L#@%O0]Z^K?A?I_B/2/
M&AV'BR]L]1\0VMLL-Y>:>6\F5E^4,-P#9( SD=<UV-%-R<MP/DYOV%?"WB[X
M_>/?'7Q!T;0_%NEZV(SIME<)(TUNR_>)Z#GV)JY\!_V0T_9Q^-WBK7/![:1;
M^ ?$$8==+='%Y8SC_EG"VW'E9SP6R*^I:*?M)6M<#R+]J#X3ZG\=O@)XP\!Z
M7>6NG:CK-M'%%<WN[R8R)D?+;06Q\A' KE?$7[%_@/QYJ?@/6/$^GK<ZUX;M
M+>VG:V)6#4/*1=JS*<;U#JKC/]VOH>BI4I)63 \%^%OP"U/X?_M"?$3Q[)?6
M4VD^)88(K6TM]PEA"8^]D  <=LU>_:G^#WB;X[?#^U\&Z'KEIH.DWUTO]MW,
MK.)I+5>L4052,MWR1T%>V44W-R=V!\2>-/\ @FAH#^&; >#_ !AK^G^)=#=)
M]!GU2]::TLY593]Q5X4@8./6OK[PC'JUKX?TN'79K>;6$@5+N2T8F)I0OS%2
.0#@]>1WK=HHE-RW _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>stro-20250313.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-13T15:10:25.7030+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.sutrobio.com/20250313" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:stro="http://www.sutrobio.com/20250313" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="stro-20250313.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45328939969968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SUTRO BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001382101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0926186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">111 Oyster Point Blvd,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">881-6500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STRO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-;BSVNV%=P,CLV+_.9<&=K/%X8HS*#-[ UQ?2&D. [NE+?\C,?P'4$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( ,.);5H'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ PXEM6D,ILMKO    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " ##B6U:'#AEZC\!   \ @  #P
M    @ %G$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ PXEM6B0>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ PXEM6F60>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="stro-20250313.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="stro-20250313.htm">stro-20250313.htm</File>
    <File>stro-20250313.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "stro-20250313.htm": {
   "nsprefix": "stro",
   "nsuri": "http://www.sutrobio.com/20250313",
   "dts": {
    "inline": {
     "local": [
      "stro-20250313.htm"
     ]
    },
    "schema": {
     "local": [
      "stro-20250313.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "stro-20250313.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "stro-20250313.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sutrobio.com/20250313/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000950170-25-038879-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-038879-xbrl.zip
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MNZ:VP&YP+9T+WPPUUQ6Z9G<<3W-[MJ[IENN(CM<QK.79#2<4XSE0D9]FP"Z
M)]H01AG@9UK )]H$0*&)>%T1^)6G_@!8M$6YF3MLCHU6?Y%:?3J4:3^.O>R>
M:W$'>,,%G@%6<3%8[W4UW[.XZ0.3!?Z3V4M%^4_%A<PPV9(?P9NE<LV=BW]
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MLZ#V"3I?N ^@B!0L7&BS^72IXMH7(SJ<7%P3I^"&(9$CR '3,-?BS'*_,6D
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M$O)T[.<@R^*+YHSGS[/H4B/3']5.Q6ZMZ7$E@!?NIPD@I$(ZJB<@XG'(B\%
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MMM"2HFJ/LL)>7MAME9++Q2MR-O&2%<9+OHJ SAVZ.UIRDYK?KE2Z1]CD,[H
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MLHR_1,F2@(K7"G\[*M!)CTN"U,=6P("(5GOPP%\Y"EB9(F5!HZYCP8J#C+[
M;,%@UZL"ERU4<F?>0:L4E@DVW^<7]*I<KB20#\SDVD=_-AY0%7WR\Y) W3%X
MJ8Z!$RL4#A[X4H;=#H>8*1 6%"YYB'R>6H\F&6&NGQ0,$ZE821#_@H9A1<B)
M"H@3;>(\!49UN6JZO>=Y 68OZOQLE5+?,/=XY/"U ?%S0D!9K%2(G\>8C6!
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M8/L0#LHLG71<9$6P*J$K<W<$Y*SN5274Y1D] O<2!6P?!J0JSR<]*#.R5Y7
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M^%H"#R(<:\$](#27:1*'['L91G,>+SC[)%#'*O8A]7WVOX+'K-UJ=]@'&?#
ME=R'"U3JPP4\\-CWJ9*!4(K] [KJ8W=5 ;*Y(V;;ZLY@":#A/VKX^O$CF<#W
M[J/(X:;=LIUQMA)X$(1IX J/<>@OVBDSZ3)<$]/0ER&+Q96$H<=Z%<"SF0Q8
M%,LP!H/R#XY&)0NG['H.QLJR$5X'\*   9F)0,39]Q?OWL(MX2SF"S5F_Q1+
M!C#RF5A ?Y@[Y\%,J,U^* 8&4X*/A?X$F>5:=/KLDWEBZ=UGL)((%]+ WG(U
MMY@+/YGX/957W(<+,JZ&,7X1N64OW!3E%<5,H5R]$ZY83$3,'-O*^!X^_,:Q
M>\TA@QZ#W <6NY;)/'MTG ;7?,G$323<!"14!@DLG(3Y@JN$_:N#C^A9\+WK
MIVB@0?M@NLF(X\7P/*$2&(UBTSA<P%52Z86D[7MP%O0B46Q7P@V&_Y24NL^8
M(GUBDC2<0W ?-U,&@_<V#*8B%J#X@&K  DU"#Y@&N*4]:K58U%PTV2^?7[/N
MZJ_WGV\Q!0DBT=)WES__^OD?[/+B)_;AT\5/;S]>OOW98OC(:=-B/_+8G3/;
MT<JNNQ(@MN,,6>QCX#;9R^SC,&;)7+"WX2+BP?(5>_G3Q>6[BW^-V.7G3S^_
MLD#)L3# ,<^6H,OT12P"52:@YZ#>5#9\X<HI&)2HD8/P2OB-:0@M)5I%ZABH
M%Z>H"X/?TAGH2\5>@KFHX/'92HBU>X8Z%]3Z=.64Q;E3-LT[.47O;;GRWK"U
M6*#0LDGALLU7+EN3?5Z/BW%?;5K!^#0<C2\*V_;K[6*\][9MC#W?:Q++2/C0
MMR:[P/%OT< U&"%L(MA<^-Y7<0(8))Y4;@H#U;W(GXWX;74(<!5\@=U.XM1-
MTC@S5S*C'08J(M6L\S(J"X><)G1P9U#D=OR#\"+IV;5MM'.&/]G['>?LQ[5S
M=KERSDH"WE&PNMCOEUJYBIYS3[NBC_)U]_BTX/YJ51VCI@OAZ\&@Z11?Y\[Q
MI8B2O!>MK!?-;!)S-UBJXWK"37,=B3-)9M5C3N93V2=Q)8)4E 238T+ KH$E
MONFUFZT5;11&N+:_1>#!4M]#9+O48W>=9O\QSW#RD!Q>EEGY"[#9$Z9K&N!Z
M,'0#I!K?7V(#>-D%&+1 +6J;831EXM>?N8)K^2P6.A;=9!]2L(C%GJO!$16!
M0G,Z R&%'L9K EL]0EGZ<DUOVKGP/!V^!I/I[H=BM!L\ V5E9O_41\,<AH20
M\=S#T-%PZ'(^9CT"N<"VX8NB5^#RA+- %HY'&D$_@L3:(-ZL>R$\*5YW&CJP
MU)TGR[\$@S\-X?T<:5<5Y.L]Z'J0TEI;9Y_#!%9PN,)$Y)A\%?6Q:_#LP=1J
MM9K=NRVQ=L?9H=3[J# +8:P#'L!\8'!!AV 8C<Q$W.PB+'[W2V/"%3P+6X5O
M5N$):'F#AY$>/ &0@INW(BH@G7@SHO%-O]F^;R1KBU/?_DVO.5A?#GR&QJ.\
M$O[2*J(FQ4AP8,_'&KL32QRL)D<E=/@K&QHT&T::]58/UB!T-S4:7II%:_P,
M  \D0^HP$/1[^\[.8#VM1* E&/RI+,;-")LF43 %P+I0(_/\&^W>%5; 1DQ3
MVS&XYNZ)@&:QULP$VPDKPE*$#^1"?P?4, $:[+0T2736:X:]#15:<1[<J#.A
M*ITH\'"A+SX&@&%H?PAOW9>M1BQ<[!.)90?:.(S%-'13S7,^+%D7%O#FFB^"
MH2!G,US)R68@.%C[M9MIWVT?5T>;PS2&MGY/P7 #\@$6.*3;:_CR(>XX?N!L
MG0UXB]F =R+ATE\3A^$@'<<$VUBIVDV:(VOP6YD3I*-K,7'U6GTX<9(94L4-
M,LBR4V@#Z$9T<@AHBU_!!.CX6C*/PW26>:& I&)_X8MHS-Y?:>I4PBV,)+S@
M8W"%2S]6FC8WOLA'DB7BAF.%/<"$&79V4SV<-0YT?7W=5!A^G,BP"32[$C_#
MU%>378#)!B8>,#KJH,CGRU4&;3US:#^N:-QI,9 -\*^GR. X)>A#)T3"&X/'
M[2:NSY7"XO29:&QOA(">;^Q'V=A],O7%3<.3<;84<!M#N@C&GE0X+R/\]E8A
MN][ LK5KI0L?_):"GIPNBQ[J6QM@1IFRG<7, L&LU'M=\#U?[=S(AR(#S PW
M5 +62[8-9?L+0#C[.)MTO85#+Y,1]\$>4K09B38CT68DVHQ$FY%H,Y+!FY',
M=_,N)L#9NS5XM)_(:!MY;\6DA3418,U@Q$HHS"D60:@P"V]C:5X('+J\%80&
M?U 'VY6 NSRA8- Z_ 3^K'9+8#0B!>I5.J6)VV'00V77<_!DE"MSOS=@7JC]
MFP@,*IW)R\1J[5_B*.""1I3&8'^!&RO<>:!K-ZT\>: C4L+W&]-8"/8?Z)52
M;S_ XNUWQA;NW[F2F&# X801NK-I (:!;G42AQSSH7GKX'8% AK,0N<!DPN\
M&S.T^?<89HMUW_-^(G[<N\+B,@R>,7 YP?9G@L?^$@W5V49%(R"F"TGA*6#'
MX-@UIBDHIX@O?>C)P[6E;IA&?A$RQ,+0QA7W4[&[)0,?#'8L= 5FKLC2SF6$
MF=JY=.<,[I(>9FJQQA.%1 9IF"I$"Z.9<#-T53]L8Z!X D >.M05-.P2:&#.
M+F$D'V*$ &2ER3X KHLP%ILQ"0O0]OWP.G\6")<*=3G>0GB2Z\EN3\=_O\Q]
M=@M+>-&&2]BN*W]N/_?<3I+)O'6BTLXPON9@&_\0AE]PT5TF(,<Z_E\2F(X4
M992X>K%>'/F<*Z&7-9>!SC]JQ/P<,;5"3/-(GLE<"![D91GX9\; [ECQJ6"@
M,H!<LH^\<<:I2C--?O4OL;Q".EG71+(?X)]9%I'\)#3W7[A:;=C#87>#NRTV
M 6,B"!/FRX7,$B[65AX"]4R1$T%FVYL@X9B9U2UOZ@41Q$ \V05P9Q:IQ"MU
MQ\8;I2A%(7V&"WRP:B4OV;= BR%E2:Q3R5DM2R'-4I\G(3#M%%S.8*;&#'@1
MN$I3?E[<KL'*$SVKZ\%[G>=9'0 UQ*G$%G(MI.Z,N18L#3K$TS2>,7X$CT6@
MMYY5["+8P@HOSK0"CEYK9Y[EL#;OS8HS-Y2FW$AF?T6GQOK"-<3B1NKTD98V
M'J137B3<X#?MK6NE NKD+>C/</O^8F>$C))LNM;R,<V*GU;IJE5"<+R_I_N2
M96/=0!9/77T=JKQ,U=U)]'&E]5=2:.);V;TFN_#]S86652XE<QC<YJ=34.(8
M9]>"AGCHW./&%0G:2Z#U?0]CPA[6/7GW+&AL%V2JB/,7>8<)6" P__GCUH/,
MS8583/VB+):I%.R#>R@#.Q@#P80!^H#65CLNKJ*$S<!(@ D2HI@:':)6UGHI
MY=)F,1_%4@.1+V PZ\#&TI8#FH@8^G;GV/F-*K5;8I'MJ8&'@)6P-A!OR_Q*
MM#<7881TA@M;P?#GF)+!]"UR08S\J2V:^\!0Z>0W0 _MW%BJ+YG$K&[7BT;#
MON (4*K$?JG$Q8 $M^(Q''LQ-+U+9CH%$4)#&S<F<=W+/+>,AC',*-)_-HDX
M&7?.X29!WM7C(C&>UR/>[FT67L/O,_LW,R5ODX"5+XYLY6Z7_^V=C\R7X+E\
M%+-3K,/%0L1H.6X4]>QIT\HY1O,7ZMO'T%:>\%<+[OO%FMV@&VNM&3*%@$H%
M>JK2*((9<>=<!GEM^QZ*DP4B]R&ZP%DH'I/71OZ1B<VF;LCG:PNQ#&GT62;+
M.V=C_]JY4\WJ87Y%MZ?ICH^X(<O:H\H6\M8EL_"K'@TC283V2[ N5F1+!3X$
MJD#&*$CAUB/6 K/K(N6\+>-,%19]S'CZKE4!2+NQG @OKZ/%-M$K0C0+@^D3
MW,L^P-##6*TL)IPE\*P+3E\SYA255KZ,P?S4ZPW_7:F5#8L*^_/^)CMW A^P
MD-JNT)E@)>[C;!4)_@7<+BP:7ID5VO_3O^^:CK< S8:;\"^Z4(^%$[\P[9*L
MG$9IIDXC_<Q[R4=EMVB%D^L%O-65,< #5P'>F\E-_4 DY7!*VRO(&37-&2WJ
M)&"A &.[24G .0H6[_$A[-_8:)UAN",L7D<H7O:ZK5=LT'8:_=[ -HZ^_^M<
M_'U6%A>ZO;_?4Q]%VLRXY7D:;?8C1N-)E;WX[F*Q9-^' 48SZ@S##\N8L\M5
M!?V%!X8^N.B&0-+M.:Z]'Q+]! \<Y\S;&VGW12?A5.C+8RXA\#"UV/S=!^QX
M#M@6QQ*YUJ>DD49MBGRW=L:\V]PSATL5QV445*HX+FTI'E4<4\4Q51Q3Q7'%
M::[$KS_8M;B.4;]Z=E/;,(Q$7L9QN55BDA^)@EG/]4&([WARRMAT&>![^6O
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M'1E67*TM;N8&N6^9%W9;6^^T6*UB<9M8&MOY+1"Y<#M8[9:21&&9H"A21K5
M+ #E0.[7LNX%N0[A0YGAE[09MP#5:W?X8$X?^Q'@YE816EYR<*/!H7RJWNU_
M:1UG=?F[+F:YF63U1'07CW2.4^<X+;GMYZK= Y5LY"YVUS?N\=F-HC_35%A6
MM3X I\H4I6N9T&NTB<5B7$&;/%6S".43NEN@);:E*N2483E;H0(LBJ4R7OBH
MGBN8",S4:=P*:JMO73.>9=E8%BY3=:\;71YP<W>U'YU2?K:VS5?7;FNI8TM;
M*37INE-H;$M'6X-IDM2 (L025]^W(EE\%.*KJX[CP?'QX_OA>]6::JP53*I*
M'!BW/3NVM.D )L$-?.? 3TJO\4@ /I?PK3R((;Z-%D2=Y>DLS^UQ&^A"/B5>
M:J&MN8V.(WSKMA,:>&X['V&9,FX.MK4FW+<@<?7*MH3;-1VI=V2A5D BSW%*
MH9IG'WO:MK%[ME9ZK<')S^)N&YM\0@:]V^??[?/O]OG?WC*Z??[=/O]NGW^W
MS[]-"^[V^>_>R>CV^;=((/Z,V87[N.9O*Z/R4F;HPO+D&TJGM 9;Z&"V#F:[
M._Y_5\^2L!?7.?@H$EN.M+%6!D_?J7IO()BF KMK@TIB*.M3=0PEE!VK8&I%
MS=\?[E%7C\,C?^K.@)UC&Y.J/8NF= UB4MB[DWJ.4ME#U6=T):L$ <"$.MC0
M# I!.[G@UXV[0_+E!NBIG#6:IR+X5>4$&HVW[ZC9=F.S62$PT60[@-_.:4?=
M%IA.V^U V_WBNN0^7^F WT)=]USH')Z(V>544DW64J=P/!2AKCVH$0GU3_&]
MCANMD^O'E'[)T1#48(6VJ!I=:[ZL;*-DFR;WV>?!IC-0_<$/-YWX0,]/I.\?
M9=<M:O-8)@T^X3P'2LQC&)R5*4Y94@Z>J1DO).A:6ZU&*YN(A<+C$]@VE=3%
M-^V);V[]: /*8L7H$W!J?5X_2XS2<&(2D"7^^+EBUJ;Z&V1FSW!"D;2Y0$RD
M-7)D]5P74%*SO_,T'[,7,V)P+:H&<GC!*Y)=/$<!A:CVQ5J*#6: QTKA9.MJ
M;J=,-Y_/!QM1U):IX0$[0U<RB$$OT<$I8.F6J=CJS6$1=N6D'>R!AEZ ,Q3Y
M\Z8$OL%!RV&3-73L'JF5.]J%, '[MWI\7/LADEU74.]^/^WJ87\]>R061D,0
M76GP?GS<IS+GANE @2>S6-O1 4J:VLQ!D+& +["W'$5\Y([@^5,\%R6$;[HZ
M[P;-ACWP0P?2&:.,A8J4CG=_!JNU:;@*N*"?ET6N-!X4$L09]>C$%GP^4ERV
MT_LOG?MQ_A+$]O'AN.>/T;+M3):.VH*>.BD4GO#AGU[Y8U0YDN'I%W W=O!T
MWV-D6]#<O7>(>X[I"!&*5QG8 0A$K">)X<=4+*L9@6(KS5C6FKQ^]%C$0)5Y
MXJ/T96/4U3T5=-A9%L)4X,WY4S=BF6/S4FH:"G=1LU1[Q)?U<%6)K5D4 @AP
M,TR5VPJ5:J%85.JB=>N7;DCU#]A+H&NJJ**T<A1Z0&WJ"^O.EL0&,0BKLE2$
MTOK#^]'XITMG2'MX^N0,O/[.T'^^H6^Y=;[/3O_=F+F7MN%T_Q>EKE K71H0
M=$(:OQ$RW5)L9#M/:6OP.&U$RPSU7G8MNON)HYBN*$:*UNT22P6GTUU=>.(;
MRVH>8:5Z =JW:LM-1D>3*G97ORWD#/7MY1)C_ 5^3&T<]4Z0<3P+R*X.3TZ.
M:L:MQR;@;64*W'*92@L"]QK8:/W,6E3]&T%;CG6.].2ZX119 9HY]56?-K["
M*VEB8SRQSJW9'Y-GZ8(;Y?Q3;%4YGOU42 )CL!F85?OVE,:IW\ 92;AGJL>(
MGX .)9N(+D:I+;$<^%Q=S\&^.*1Y7-OGY\RTWAHI>C-6:PJ.,_&M=AMCE5I2
MH_ &K?!B:S:I31FZ+]SBZO5[+7:\X<#/3YS4V%:#5B3&(S-] ^%/J<!OW&])
M'0B9&_NZEOSA>J^OM_T>;Y[I)@!_3 ^P46#U==7U/5A)/JRG-%8R#A"/0NQ9
M$S2%/B.=*-;X-,)NR, +Q&A(#\J'U*Z@9N\!'4LVP5;% AM6;1=H?"[PE$<G
ME@?+N9-8JP;^=I'5'M4H\6>&,ET&\4TJ R>(VT]5AB%U$]\,4(H,FX(7!2\(
MW%7W:BBP!@FJ1,EQ6P]"<6!+(H038/![P0DEUXJVM4+ #E$]7.4:N?M-L VV
MH%%Q$/!>EA[T.L]7K%T7PAS5&:?::YG%U&,,?'[4!07J3W+Y;B*&+B>_ ?6H
MK;S45Y9CJMLM9HID3SD2J-1;3N-#84 %5^DQ7+M?&H*NU "MWN4:XQF;[\+(
MP1T):%\BOHRM[["N(+?-F&J3;$)NTVQ;YQ?>D(WO"LR[ O.NP/SVEM$5F'<%
MYEV!>5=@WJ8%=P7FNW<RN@+S^P(^-4X>L^V($+Y81P1Z+E*V83R%<A4ZL#$X
MLYD7[H)%'ZKYH#Q-16$['G&?6=_PS)X#' C,P/5_#H;AFT.D/$E\ %_#'GI+
MF,BB0X@PP4RQ!P1VD8BI]Q/5X6W .Z2GR'HPN*0HMH\R?A@@G8+X[X-PI_ M
M@2(7O#4H9BF-&9[)8NO;V!Q(;\7<:)F?,.VH7,FHU0);RC_9J+YQR51]TM"P
M$B,HBX.]U82-F^'#'$BP6"($:T,L&6;MJ#E7EUI87,S/T8(VVT)DH'10R EV
MZ,"*?7IF[,[(\NCI.[C7G4:@*_@4WY(*2@_P+.$3;.;KZC_AK=@SZ/%GA3'5
MX%6<SXMKV^($!T@E@8R^]\D- ([.P=PPE0%_\@ICI&R9;\G2P)'7"&J7:_B5
MP.,7F)HD'N<U]LQ(3;!-F=.8-R(1VMY"Z),#B?#60!9 'JP$P_*U97T&#8@(
MC8K^4-N-^Y&/[U)5N^8 7_N%!_H94 +?"'%NI^,T#L)^Q8?>9S)LJ2JZCZ1X
M>'RT]R-[LG_0?WS\9-@Z1/DON]+?.]7B@I[WTPVE()TU:YUXWE&G)RQFZDS9
M@Z=GZ8(]4QGF.N\S&7Y9%)Q=5EV-SUQ/J):0Y.CX(!AN)LGN-EQ#R$EL\U,"
MM/--M%; XTZY?I4U/X%;/S7]MQOY^8[!GRYMW:6MN[1UE[;NTM9=VKI+6_^9
M-/=]35N?/L(M/D__>OHH-FGR]/\!4$L! A0#%     @ PXEM6@-QJ/X6(P
MGQ,! !$              ( !     '-T<F\M,C R-3 S,3,N:'1M4$L! A0#
M%     @ PXEM6D'!X"@+"0   V<  !$              ( !12,  '-T<F\M
M,C R-3 S,3,N>'-D4$L! A0#%     @ PXEM6C:T(/+/'@  S?X"  \
M         ( !?RP  '-T<F\M97@Y.5\Q+FAT;5!+ 0(4 Q0    ( ,.);5H!
M.-3&@Q8  %*\   /              "  7M+  !S=')O+65X.3E?,BYH=&U0
52P4&      0 ! #X    *V(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>stro-20250313_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="stro-20250313.xsd" xlink:type="simple"/>
    <context id="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382101</identifier>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_de36181c-a74f-4b46-a571-b8146418811d">0001382101</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_5c184e43-1ebc-430e-9bd7-17e76945928b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_f833bdec-8bd1-4289-974e-76fb7075e259">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_830aec2f-88e0-465b-8940-0385e6b61359">2025-03-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_4983a5c4-89c6-4481-b8b7-cb3a2c038dc9">SUTRO BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_40305bf9-1b23-4ff2-8d4c-7ef4e8584618">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_84046c10-d348-48df-95bb-c4c3632832cc">001-38662</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_ed92b8d3-e483-463a-ab9e-df2f838a6426">47-0926186</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_f09c9968-7357-432b-906f-e193002e8821">111 Oyster Point Blvd,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_3bb950a0-237d-403a-a24e-be8f0c56e6a2">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_760cd242-53ea-49c8-8d87-5ac2d499e651">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_7c8bd0f3-3053-4635-8a57-9fb9c2d28381">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_c3d18a38-eedf-4d44-8360-b4d7edae8074">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_ad7f8557-466a-4144-9743-7e7a82941d69">881-6500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_49fc3202-9986-429a-b0f4-feab39c4a045">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_453aea30-e46d-42be-ba5c-cd5a24f74059">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_580b5508-e6df-476e-8ca5-b550f1490db5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_2f50c4fe-585a-411a-bfcd-4f08fd341a12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_43138228-4a65-4091-9606-b1eb8671a86a">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_2babd2e4-4332-4869-bb41-a4e171862c0c">STRO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_28bb3a3c-75a7-42a5-85db-1a491bde0d8b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_19c63baf-bf5f-4464-8bc4-a51d78e2d81c"
      id="F_3b674f94-1cad-4d87-90c3-295a1bfa895d">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
